Posters et communications

  1. Saltarelli D., Cussac D., Kordon C., Enjalbert A. Binding of guanine nucleotides with membranes from adenohypophyseal cells in primary culture. Conference Jacques Monod « Molecular mechanisms of signal transduction« , Roscoff, 3-7 july 1989

  2. Saltarelli D., Cussac D., Kordon C., Enjalbert A. Liaison de nucléotides aux proteines G des membranes de cellules adénohypophysaires en culture primaire. 3iéme Colloque National des Neurosciences, Montpellier, 9-12 may 1989, Abst. C23.

  3. Cussac D., Leblanc P., L’heritier A., Kordon C., Enjalbert A., Salterelli D. Substrates of botulinum C3 toxin catalyzed ADP-ribosylation in rat pituitary cells. Conférence Jacques Monod: Mechanisms of exocytosis, Aussois, 1990.

  4. Pellegrini I., Saltarelli D., Cussac D., Kordon C., Jaquet P., Enjalbert A. Differential distribution of G proteins in different types of human pituitary tumors. 2nd International Congress of Neuroendocrinology, Bordeaux, 1990.

  5. Saltarelli D., Loudes C., Cussac D., Kordon C., Enjalbert A., Faivre-bauman A. G proteins ontogenesis in the mouse hypothalamus assessed by ADP-ribosylation. 2nd International Congress of Neuroendocrinology, Bordeaux, 1990. In : Neuroendocrinology, 1990, 52-S1 : P3.128.

  6. Saltarelli D., Cussac D., Pellegrini I., Kordon C., Jaquet P., Enjalbert A. Caractérisation fonctionnelle des protéines G dans différents types d’adénomes hypophysaires humains : comparaison avec les cellules hypophysaires de rat. 20° Colloque de la Société de Neuroendocrinologie expérimentale, Genève, 1991.

  7. Cussac D., Leblanc P., L’heritier A., Kordon C., Enjalbert A., Saltarelli D. Des proteines G de petit poids moléculaire dans l’hypophyse antérieure de rat. Identification et colocalisation dans des vésicules membranaires des substrats de l’exoenzyme C3 du botulium. 20° Colloque de la Société de Neuroendocrinologie expérimentale, Genève, 1991.

  8. Cussac D., Saltarelli D., Enjalbert A. Pertussis toxin and cholera toxin catalyzed ADPribosylation and G proteins activation in rat anterior pituitary cells. 36th Harden conference: GTP binding proteins, Ashford, England 1992.

  9. Cussac D., Kordon C., Enjalbert A., Saltarelli D. Nature et interactions des protéines G trimériques couplées aux récepteurs des neurohormones dans les cellules antéhypophysaires de rat. 1er Colloque de la Société des Neurosciences, Strasbourg, 1992; S29 : 34.

  10. Cussac D. Kordon C., Enjalbert A., Saltarelli D. Cinétique d’incorporation d’ADPribose catalysée par les toxines du choléra et de Bordetella pertussis dans des cellules antéhypophysaires de rat: effet sur l’interaction récepteur protéine G. 1er Colloque de la Société des Neurosciences, Strasbourg, 1992 ; G17 : 224.

  11. Cussac D., Leblanc P., L’heritier A., Lang P., Bertoglio J., Kordon C., Enjalbert A., Saltarelli D. Low molecular weight GTP binding proteins of the rho family and secreting pathway in rat pituitary cells. 5th International congress on cell biology. Madrid, july 1992.

  12. Cussac D., Kordon C., Enjalbert A., Saltarelli D. ADPribose incorporation catalysed by cholera and Bordetella pertussis toxins and receptor-G protein interactions. 9th International congress of endocrinology, Nice, 31 août-4 september 1992 ; P1604004.

  13. Cussac D., Leblanc P., L’heritier A., Kordon C., Enjalbert A., Saltarelli D. Les « petites protéines G » de la famille rho ont-elles un rôle dans les sécrétions hypophysaires ? 19ième Forum des jeunes chercheurs. Caen, 1992. In : Regard sur la biochimie., n° 3.

  14. Saltarelli D., Cussac D., Pellegrini I., Dewailly D., Kordon C., Jaquet P., Enjalbert A. Differential effects of Gs, Gi and Go protein activation on adenylyl cyclase activity in human pituitary tumors. 9th International congress of endocrinology, Nice, 31 august-4 september 1992 ; P1604005.

  15. Cussac D., Frech M, Paris S., Chardin P. Human ras exchange factors interaction with receptor tyrosine kinases: Studies of the Grb2/Sos complex. EMBL conference, oncogenes and growth control, Heidelberg april 1994.

  16. Cussac D., Chardin P. Specificity of phosphotyrosine peptide binding to the SH2 domain of Grb2, an adaptator protein involved in the activation of ras pathway. Workshop on G proteins: Structural features and their involvement in the regulation of cell growth, Madrid 27-29 November 1995.

  17. Cussac D., Scaife R.M, Vidal M., Garbay C., Roques B.P. Study of Grb2-dynamin interaction using Surface Plasmon Resonance binding assay. Jacques Monod Conference,Jjune 24-28, 1996- Aussois, France.

  18. Cornille F., Martin L., Lenoir C, Cussac D., Roques B.P., Fournié-Zaluski M. The allosteric-type control of tetanus toxin metalloprotease activity determines its substrate specificity. 15th American Peptide Symposium, Nashville USA, June 14-19, 1997.

  19. Cussac D., Cornille F., Tiraboschi G., Lenoir C., Roques B.P., Garbay C. Design and synthesis of specific Proline-Rich Peptides with high affinity for Grb2. 15th American Peptide Symposium, Nashville USA, June 14-19, 1997.

  20. Cussac D., Cornille F., Tiraboschi G., Lenoir C., Roques B.P., Garbay C. Study of Grb2/Sos interaction using proline-rich peptides with high affinity for Grb2 SH3 domains. FEBS Special Meeting, Amsterdam, The Netherlands, June 29-July 3, 1997.

  21. Newman-Tancredi A., Cussac D., Audinot V., Pasteau V., Gavaudan S., Millan M.J. Differential G-protein coupling of dopamine D3 and D2 receptors: a [35S] GTPS binding and antibody study. Dopamine 98, Strasbourg, 22-25 july 1998.

  22. Cussac D., Newman-Tancredi A., Pasteau V., Millan M.J. Human dopamine D3 receptors stimulate MAP-Kinase phosphorylation in CHO cells. 28th Annual Meeting of Neuroscience, Abstr, 24, 1373 Los Angeles, November 7-12, 1998.

  23. Cussac D., Newman-Tancredi A., LEjeune F., Gobert A., Audinot V., RIvet J.M., Dubuffet T., Lavielle G., Millan M.J. S33084 : A novel, potent and selective benzopyranopyrrolidine antagonist and radioligand at dopamine D3 receptors. 29th Annual Meeting of Neuroscience , Miami, October23-28, 1999.

  24. Millan M.J., Brocco M., Dekeyne A., Newman-Tancredi A., Cussac D., Lejeune F., Rivet J.M., Gobert A., Audinot V., Despaux N., Peglion J.L. S 32504: A novel and potent naphtoxazine agonist at dopamine D3 receptors. 29th Annual Meeting of Neuroscience , Miami, October 23-28, 1999.

  25. Newman-Tancredi A., Brocco M., Cussac D., RiveT J.M., Chaput C., Touzard, M., Millan M.J. S 32504: Dopamine D2/D3 receptor-mediated G-protein activation in rat caudate nucleus is increased by a unilateral 6-hydroxydopamine lesion of the substantia nigra : a [35S]-GTPS autoradiography study. 29th Annual Meeting of Neuroscience , Miami, October 23-28, 1999.

  26. Millan M.J., Lejeune F., Cussac D., Gobert A., Newman-Tancredi A., Rivet J.M., Adhumeau A., Nicolas J.-P., Boutin J.A., Peglion J.L. S18327: A novel phenylimidazolinone and potential antipsychotic : antagonist properties at 1-and 2-adrenergic receptors in vitro and in vivo. 12th ECNP congress , London, September 21 -25, 1999.

  27. Cussac D., Newman-Tancredi A., Quentric Y, Millan M.J. Characterization of drug activity at human (h)5-HT2A, h5 HT2B and h5 HT2C receptors by an innovative approach of [3h]phosphatidylinositol ([3h]PI) depletion. ASBMB and ASPET meeting, Boston, June 4-8, 2000. Published in FASEB J. 14(8), 2000.

  28. Millan M.J., Brocco M., Cussac D., Dekeyne A., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J. M., Dubuffet T., Lavielle G. S33138, a preferential benzopyranopyrrole antagonist at dopamine D3 receptors and potential antipsychotic agent. Congress of International NeuroPsychopharmacology, Bruxelles, July. Published in Int. J. Psychopharmacology, 3, Suppl. 1, S133: 2000.

  29. Cussac D., Newman-Tancredi A., Audinot V., Nicolas J.-P., Boutin J., Gobert A., Millan M.J. The novel dopamine D3 partial agonist , BP897, is a potent ligand at diverse adrenergic and serotonergic receptors. 30th Annual Meeting of Neuroscience , New-Orleans, November 4-9 , 2000.

  30. Gobert A., Rivet J.M., Cussac D., Newman-Tancredi A., Lejeune F., Bosc C., Dubuffet T., Lavielle G., Millan M.J. S33592, a benzopyranopyrrole partial agonist at dopamine D2/D3, receptors and potential antipsychotic agent : I. Modulation of dopaminergic transmission in comparison to aripiprazole, preclamol and raclopride. 30th Annual Meeting of Neuroscience , New-Orleans, , November 4-9 , 2000.

  31. Newman-Tancredi A., Lejeune F., Audinot V., Nicolas J.-P., Boutin J., Gobert A., Rivet J.M., Brocco M., Cussac D., Dekeyne A., Millan M.J. The antiparkinsonian agent, piribedil, is an antagonist at 2-adrenergic receptors (AR) in vitro and in vivo. 30th Annual Meeting of Neuroscience , New-Orleans, November 4-9 , 2000.

  32. Cussac D., Newman-Tancredi A., Duqueyroix D., Millan M.J. Cloned human serotonin h5 HT2C receptors couple to both Gq and Gi/o: an SPA immunodetection and MAPK phosphorylation study. Experimental Biology, Orlando, March 31-April 4 , 2001. FASEB J. 15 (4), 2001.

  33. Cussac D., Newman-Tancredi A., Duqueyroix D., Millan M.J. Functional actions of diverse antipsychotic agents at 5-HT1A receptors mediating mitogen-activated protein kinase (MAPK) activation. Experimental Biology, Orlando, March 31-April 4, 2001. Published in FASEB J. 15 (4), 2001.

  34. Newman-Tancredi A., Cussac D., Nicolas J.-P., Audinot V., Boutin J., Brocco M., Millan M.J. (2001) Antiparkinsonian agents display contrasting profiles of activity at recombinant human dopamine D2/D3 receptors vs 1A– and 2A-adrenoceptors. EPHAR, Lyon (France), 6-9 July, 2001. Published in Fund. Clin. Pharmacol. 15: (Suppl.1) Poster 9P013.

  35. Newman-Tancredi A., Cussac D., Millan M.J. Characterization of drug activity at recombinant, human (h)1A-adrenoceptors (AR) by an innovative measure of [3H]phosphatidylinositol ([3H]PI) depletion: potent antagonist properties of clozapine and the novel antipsychotic, S18327. Am. Soc. Neurosci. Abstr. 27: 45.8, 2001.

  36. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., Boutin J.A., Lacoste J.-M., Cordi A. The novel, potential antidepressants, S35966 and S35967, act as serotonin and norepinephrine reuptake inhibitors and antagonists at 2-adrenoceptors. Am. Soc. Neurosci. Abstr. 27: 975.18., 2001.

  37. Millan M.J., Lejeune F., Gobert A., Newman-Tancredi A., Cussac D., Audinot V., Brocco M., Dekeyne A., Boutin J.A., Lacoste J-M., Cordi, A. The novel, potential antidepressant agents, S35966 and S35967, interact both with 2-adrenoceptors and with serotonin and norepinephrine transporters. Eur. Neuropsychopharmacol. 11 (Suppl 3) S196, 2001.

  38. Cussac D., Newman-Tancredi A., Duqueyroix D., Millan M.J. Characterization of recombinant, human muscarinic (hM)1 and hM4 receptor coupling to specific G-proteins by a [35S]GTPS binding-scintillation proximity assay (SPA): antagonist properties of clozapine and the novel antipsychotic, S33592. Am. Soc. Neurosci. Abstr. 27: 45.9, 2001.

  39. Peglion J-L., Harmange J-C., Cussac, D., Millan, M.J. S32504, a preferential agonist at dopamine D3 versus D2 receptors posessing antiparkinsonian and antidepressant properties. Am. Chem. Soc. 22nd ACS National Meeting, Chicago, Illinois, USA. 26-30 August, 2001.

  40. Newman-Tancredi A., Cussac D., Marini L., Millan M.J. Stimulation oof G protein Gi3 subunits by h5 HT1A receptors expressed in CHO cells: agonists display bell-shaped concentration-response curves. Br. Pharmacol. Soc. 135: 188P, 2001.

  41. Newman-Tancredi A., Cussac D., Touzard M., Chaput C., Marini L., Millan M.J. G protein activation by h5 HT1B receptors expressed in CHO cells: scintillation proximity assays reveal constitutive Gi3 activation. Br. Pharmacol. Soc. 135: 187P, 2001.

  42. Cussac D., Newman-Tancredi A., Pasteau V., Millan M.J. Antagonist properties of the melatonin agonist, S20098 (Agomelatine) at recombinant, human (h)serotonin (5-HT)2C receptors. 23th CINP congress, published in International J. Neuropsychopharmacology 5: P1E.064, 2002.

  43. Gobert A., Cussac D., Lejeune F., Newman-Tancredi A., Audinot V., Boutin J.A., Carr C., Milligan G., Rivet J-M., Brocco M., Dekeyne A., Lacoste J.-M., Cordi A., Millan M.J. The novel antidepressant, S35966, is a mixed serotonin and noradrenaline reuptake inhibitor and an antagonist at 2-adrenoceptors. 15th ECNP Congress, October 5-9, Barcelona, Spain, 2002.

  44. Millan M.J, Rivet J-M., Brocco M., Cussac D., Dekeyne A., Gobert A., Lejeune F., Newman-Tancredi A., Bertrand M., Peglion J-M. The novel, highly selective serotonin (5-HT)1A receptor ligand, S37245, is an anxiolytic with potential procognitive and antidepresive properties. 15th ECNP Congress, October 5-9, Barcelona, Spain, 2002.

  45. Millan M.J, Dekeyne A., Chamorro S., Longchamp M., Levens N., Cussac D., Newman-Tancredi A., Silverdale M., Brotchie J., Dubuffet T., Lavielle G., Brocco M. Antipsychotic profile of the novel benzopyranopyrrole and preferential dopamine D3 receptor antagonist, S33138. 15th ECNP Congress, October 5-9, Barcelona, Spain, 2002.

  46. Cussac D., Amphoux A., Hubert D., Newman-Tancredi A., Millan M.J. Differential efficacy of antiparkinsonian agents at dopamine D2L receptors suggested by G protein but not MAP-Kinase activation. Am. Soc. Neurosci. Abstr. 28: 542.1, Orlando, USA, 2002.

  47. Newman-Tancredi A., Cussac D., Millan M.J. Antiparkinsonian agents exhibit diverse profiles of agonist and antagonist activity at human, serotonin h5-HT1A/1B/1D and h5-HT2A/2B/2C receptors. Am. Soc. Neurosci. Abstr. 28: 787.17, 2002.

  48. Millan M.J, Cussac D., Newman-Tancredi A., Gobert A., Lejeune F., Rivet J-M., Brocco M., Dekeyne A., Silverdale M., Brotchie J., Dubuffet T., Lavielle G. The novel benzopyranopyrrole and antipsychotic, S33138, is a preferential antagonist at dopamine D3 versus D2 receptors. Am. Soc. Neurosci. Abstr. 28: 894.14, 2002.

  49. Millan M.J, Cussac D., Maiofiss L., Audinot V., Boutin J.A., Bodjarian N., Newman-Tancredi A. The antiparkinsonian agent, piribedil, possesses a distinctive profile of dopamine D2/D3 agonist and 2-adrenoceptor antagonist properties: A multivariate comparison to other antiparkinsonian agents at recombinant, human monoaminergic receptors. 7th International Congress of Parkinson’s Disease and Movement Disorders, Miami, Florida, USA, November 10-14, 2002. Published in Movement Disorder, Vol.17 (Suppl.5), P39 : S28., 2002.

  50. Peglion J-L., Dessinges A., Cussac D., Newman-Tancredi A., Audinot V., Millan, M.J. Unique profile of a preferential dopamine D3 receptor antagonist displaying extraordinarily potent antimuscarinic properties. International Medicinal Chemistry, Barcelona, Spain, Sept 12-15, 2002.

  51. Cussac D., Chaput C., Marini L., Millan M.J. 2-adrenoceptors couple to Gi3 and Go proteins in stably-transfected CHO cells: an antibody capture analysis. Gordon Research Conference on Catecholamines, Oxford, UK, August 3-8,2003.

  52. Millan M.J., Di Cara B., Gobert A., Del Signore S., Bonhomme C., Cussac, D. Piribedil, an antiparkinsonian agent with D2/D3 dopamine agonist and alpha2-adrenoceptor antagonist properties, increases noradrenergic and cholinergic outflow in frontal cortex, as compared to other anti-parkinson drugs. 7th EFNS Congress, Helsinki, Finland, September 1-5, 2003.

  53. Dekeyne A., Di Cara B., Gobert A., Cussac D., Millan M.J. D1 receptor agonist raise cortex Acetylcholine levels and reduce amnesic actions of the muscarinic blocker scopolamine. 10th Biennial EBPS Meeting, Antwerp, Belgium, September 6-9, 2003.

  54. Millan M.J., Dekeyne A., Gobert A., Di Cara B., Audinot V., Cussac D., Ortuno J-L., Fauchère J A., Boutin J-A., Brocco M. Actions of the selective melanin concentrating hormone1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic in rodents. 16th ECNP Congress, Prague, Czech Republic, September 20-24, 2003.

  55. Millan M.J., Newman-Tancredi A., Cussac D., Milligan G. Contrasting actions of agonists and inverse agonists at cloned, human serotonin (h5-HT)1A receptors coupled to Gi compared to Go: a fusion protein analysis. Am. Soc. Neurosci. Abstr. 2003.

  56. Cussac D., Amphoux A., Pasteau V., Millan M.J. Efficacy of antiparkinsonian agents at 2A-adrenoceptors determined by MAP-Kinase phosphorylation. Am. Soc. Neurosci. Abstr. 2003.

  57. D. Cussac, L. De Vries, S. Bernois and C. Palmier. Functional heterodimerization between µ-opioid and 5-HT1A receptors revealed by co-immunoprecipitation and trans-activation of Go proteins fused to receptors. 34th Annual Meeting – Society for Neuroscience. San Diego, USA, 2004.

  58. Boutet-Robinet E.; Rauly-Lestienne I.; Ailhaud M.C.; Newman-Tancredi A.a; Cussac D. Differential properties of novel and commercialised antipsychotics at human 5-HT7 receptors coupled to adenylyl cyclase. CINP Meeting, Paris 2004.

  59. P. Heusler, P. Pauwels, T.Wurch, A. Newman-Tancredi, J. Tytgat and D. Cussac. Differential activation by human 5-HT1A receptors of ion currents in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. FENS, Lisbonne 2004.

  60. I. Rauly-Lestienne; E. Boutet-Robinet; M.C. Ailhaud; A. Newman-Tancredi ; D. Cussac. Agonist-directed trafficking at 5 HT2A, 5 HT2B and 5 HT2C receptors revealed by differential activation of Gq/11 proteins compared with Ca++ release. EPHAR, Porto 2004.

  61. Newman-Tancredi A., Ormière A.-M., Robinet E., Cussac D. SEROTONIN h5 HT1A RECEPTOR-MEDIATED GI3 SUBUNIT ACTIVATION: BELL-SHAPED CONCENTRATION-RESPONSE ISOTHERMS ARE DEPENDENT ON RECEPTOR EXPRESSION LEVELS AND CELL TYPE. EPHAR, Porto 2004.

  62. Rauly-Lestienne I, Boutet-Robinet E, Ailhaud M.C, Newman-Tancredi A, Cussac D. Differential properties of novel and commercialised antipsychotics at human 5-HT7 receptors coupled to adenylyl cyclase activity. EPHAR, Porto 2004.

  63. Didier Cussac, Luc de Vries, Frédéric Finana, Sophie Bernois, Christiane Palmier D116A (D(3.32)) mutated 5 HT1A receptor displays RASSL (Receptor Activated Solely by Synthetic Ligand) properties. Neurosciences Française, Lille 2005.

  64. J.C. Martel, A.M. Ormière, M.B Assié, D. Cussac, A. Newman-Tancredi1 Spiperone and methiothepin act as inverse agonists on native rat hippocampal 5-HT1A receptors coupled to Go protein. 35th Annual Meeting – Society for Neuroscience, Washington DC, 2005.

  65. L.A. Bruins Slot, A. Newman-Tancredi and D. Cussac. Effect of novle antipsychotic agents at dopamine D2 and serotonin 5-HT1A receptors: Measure of MAP-Kinase phosphorylation. 35th Annual Meeting – Society for Neuroscience, Washington DC, 2005.

  66. Rauly-Lestienne, I., Lestienne, F., Ailhaud, M., Lauressergues, E., Binesse, J., Riant, E., Newman-Tancredi, A & Cussac, D. Modulation of GPCR transduction pathways using RNA interference against Gsubunits. Gordon Research Conference on Molecular Pharmacology. 3-13 May 2005, Barga, Italy.

  67. Martel JC; Leduc N; Ormière AM; Assié MB; Cussac D and Newman-Tancredi A. F15063, an innovative antipsychotic with potent D2/D3 antagonist, 5-HT1A and D4 agonist properties: in vitro pharmacological profile and functional autoradiography in rat brain. FENS meeting, Vienne, 2006.

  68. Newman-Tancredi A., Assié M.-B., Martel J.-C., Cosi C., Heusler P., Bruins Slot L., Carilla-Durand E., Cussac D. F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I) Receptor affinity and efficacy in vitro and activity in neurochemical and neuroendocrine tests in rodent. 19th ECNP Congress, Paris, 2006.

  69. Newman-Tancredi, A., Martel, J.C., Rauly-Lestienne, I. & Cussac, D. High Throuhput GPCR pharmacology; Using GTPS assays to assess GPCR activation.. British Pharmacology Society, London, England.10-11 April 2006.

  70. Pignier, C., Revenaz, C., Rauly-Lestienne I., Cussac, D., Gardette, J., Delhon, A. & Le Grand, B. Does fastening of the inactivation process of persistent sodium current and ultra rapid potassium current constitutes the antiarrhythmic mechanism of PUFAs ? World Congress Of Cardiology. 2-6 september 2006. Barcelona, Spain.

  71. Newman-Tancredi A, Assié M.-B, Cosi C, Bruins Slot L, Cussac D, Martel J.C. F15599, a highly selective serotonin 5-HT1A receptor agonist : I) in vitro affinity and efficacy profile at native rat and recombinant human 5-HT1A receptors. 19th ECNP Congress, Paris, 2006.

  72. Newman-Tancredi A, Assié M-B, Martel J-C, Cosi C, Heusler P, Bruins Slot L, Carilla-Durand E, Cussac D. F15063, an innovative antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I) in vitro, neurochemical and neuroendocrine profiles. 27th CINP congress, Chicago 2006.

  73. Didier Cussac, Peter Heusler, Jean-Claude Martel and Adrian Newman-Tancredi. The new antipsychotics, bifeprunox, F15063 and SLV313, behave as partial agonists at dopamine D4 receptors: comparison with typical and atypical antipsychotics. 36th Annual Meeting – Society for Neuroscience, Atlanta, 2006.

  74. Luc De Vries, Claudie Cathala and Didier Cussac. Vindeburnol does not activate the rat tyrosine hydroxylase promoter. 36th Annual Meeting – Society for Neuroscience, Atlanta, 2006.

  75. M.B. Assie, C. Cosi, L. Bruins Slot, D. Cussac, J.C. Martel, R. Depoortere, E. Carilla-Durand, A. Newman-Tancredi. Pharmacological profile of F15599, a highly selective serotonin 5-HT1A receptor agonist. 36th Annual Meeting – Society for Neuroscience, Atlanta, 2006.

  76. Martel J.-C., Cussac D., Assié M.-B., Rauly-Lestienne I., Newman-Tancredi A. Antagonism of serotonin 5-HT2B receptors: activity of atypical benzamide antipsychotics in comparison with 5-HT2A, 5-HT2C and dopamine D2 receptors. 36th Annual Meeting – Society for Neuroscience, Atlanta, 2006.

  77. Peter Heusler, Annabelle-Castro-Fernandez, and Didier Cussac. Highly differential profile of antipsychotic agents at human D2L receptors coupled to GIRK potassium channels. Keystone Symposium, 2006.

  78. Jaroslava Buritova, Adrian Newman-Tancredi, Christelle Buquet, Geraldine Berrichon, Didier Cussac. Region-specific effects of F15599, a selective serotonin 5-HT1A receptor agonist, on the phosphorylation of MAP-kinase (ERK1/2) in the rat brain: a quantitative ELISA study. Neurosciences Française, Montpellier 2007.

  79. L.A. Bruins Slot, F. Lestienne, C. Grevoz-Barret, A. Newman-Tancredi, D. Cussac. F15063, a potential antipsychotic with dopamine D2 / D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: Influence on expression of immediate-early genes in rat prefrontal cortex and striatum. 37th Annual Meeting – Society for Neuroscience, San Diego, 2007.

  80. J. Buritova, E. Lauressergues, G. Berrichon, M. Sammut, A. Newman-Tancredi, D. Cussac. F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors: I) activity on ERK1/2 phosphorylation and c-fos induction. 37th Annual Meeting – Society for Neuroscience, San Diego, 2007.

  81. Peter Heusler, Tatiana Muñoz-Delgado, Timothé Loock, Adrian Newman-Tancredi, Didier Cussac. Agonist and antagonist properties of antipsychotics for internalisation of D2 and 5-HT1A receptors. 37th Annual Meeting – Society for Neuroscience, San Diego, 2007.

  82. Didier Cussac, Jean-Claude Martel, Marie-Bernadette Assié, Peter Heusler, Isabelle Rauly-Lestienne, Marie-Christine Ailhaud, Nathalie Danty, Nathalie Leduc, Anne-Marie Ormière, Gaëlle Pulou, Stéphanie Tardif, Adrian Newman-Tancredi. Distintive affinity profile of novel antipsychotics possessing combined D2 and 5-HT1A receptor properties compared with conventional and atypical antipsychotics. 38th Annual Meeting – Society for Neuroscience, Washington DC, 2008.

  83. Adrian Newman-Tancredi, Jean-Claude Martel, Marie-Bernadette Assié, Laurent Bardin, Agnès Auclair, Thierry Imbert, Pierre Sokoloff , Didier Cussac, Ronan Depoortere. F16615, a D2 antagonist, potent 5-HT2B antagonist and 5-HT1A partial agonist: In vitro and in vivo profile of antipsychotic-like activity. 38th Annual Meeting – Society for Neuroscience, Washington DC, 2008.

  84. Auclair A.L., Buritova Y., Cussac D., Assié M.-B., Depoortère R and Newman-Tancredi A. F15599, a highly selective serotonin 5-HT1A receptor agonist that preferentially targets post-synaptic receptors in the frontal cortex: biochemical and neurochemical profiles. Serotonin Club, Manchester, 2008.

  85. Peter Heusler · Liesbeth Bruins Slot · Isabelle Rauly-Lestienne · Christiane Palmier · Stéphanie Tardif · Amélie Tourette · Marie-Christine Ailhaud · Didier Cussac. Activation of G proteins and Extracellular signal-Regulated Kinase1/2 phosphorylation via human dopamine D4.4 receptors: Differential pathway-dependent potencies of receptor agonists. EPHAR, Manchester, 2008.

  86. L. De Vries F. Finana, Didier Cussac. Study of the interaction between TrkB and Shc by a BRET assay. Gordon conference, Boston, 2008.

  87. Newman-Tancredi A, Martel J-C, Buritova J, Lauressergues E, Assié M-B, Bruins Slot L, Cosi C, Heusler P, Cussac D. F15599, a 5-HT1A receptor agonist that preferentially targets post-synaptic receptors in the frontal cortex: I) receptor interaction and functionally-selective signal transduction profile. ECNP Barcelona, 2008.

  88. E. Lauressergues, Didier Junquero, Dean W. Hum, Zouher Majd, Patrick Duriez, Bart Staels and Didier Cussac. Antipsychotic induced-hepatic gene dysregulations correlate with clinical metabolic side effects : a hypothesis of direct action on liver. CINP, Munich, 2008.

  89. Martel J.C., Ormière A.M., Leduc N., Newman-Tancredi A., Lestienne F. and Cussac D. Promiscuous coupling of serotonin 5-HT1A receptors to G-protein subtypes in rat brain structures: Potential agonist-directed trafficking by selective ligands. CINP, Munich, 2008.

  90. Michel Perez, Marie Lamothe, Ian Rilatt, Clemens Horn, Didier Cussac, Luc De Vries, Christophe Pignier, Florence Nadal-Wollbold, Robert Letienne, Arnaud Bocquet, Bruno Le Grand. DESIGN AND SYNTHESIS OF NOVEL, ORALLY ACTIVE, PIPERAZINE-DERIVED PAR1 ANTAGONISTS AS ANTIPLATELET AGENT. XXth International Symposium on Medicinal Chemistry, Vienna, 2008.

  91. Rauly-Lestienne, I., Lestienne, F., Barret-Grevoz, C., Ailhaud, M.C., Auclair, A., Depoorter, R., Newman-Tancredi, A. & Cussac, D. Downregulation of 5-HT1A receptors by a siRNA/shRNA approach validated in vitro, failed in vivo. Colloque de la Société des Neurosciences, 26-29 mai 2009. Bordeaux, France.

  92. Cussac, D., Assié, M.B., Auclair, A., Depoortere, R., Rauly-Lestienne, I., Martel, J.C. & Newman-Tancredi, A. Aripiprazole modulates citalopram-induced 5-HT release and MDMA-induced hyperactivity, potential role of 5-HT2B receptor blockade. Society for Neuroscience. Chicago, 2009.

  93. Jaroslava Buritova, Geraldine Berrichon, Didier Cussac. Pre- and post-synaptic 5-HT1A receptors modulate Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: Role of the MEK signalling pathway. Pain in Europe Meeting, Lisbonne, 2009.

  94. Jean-Claude MARTEL, Anne-Marie ORMIERE, Didier CUSSAC, Fabrice LESTIENNE and Adrian NEWMAN-TANCREDI Antibody targeting of Gi1/3 proteins reveals bell-shaped agonist concentration-response isotherms in cell lines expressing high levels of 5-HT1A receptors: relation to receptor dimerisation ? British Pharmacology Society, Leicester, 2009.

  95. S. Vispé, S. Gras, N. Novosad, L. DeVries, F. Lestienne, D. Cussac, J. Besse, S. Bréand, D. Hobson, J. Svejstrup, J. Verdier, L. Créancier, A. Stennevin, J.P. Annereau, E. Cros, C. Dumontet, J.M. Barret, N. Guilbaud and C. Bailly. Triptolide inhibits RNA polymerase I and II-dependent transcription leading predominantly to downregulation of short lived mRNA. AACR meeting, San Diego, USA, 2009.

  96. E. Lauressergues, Bart Staels, Patrick Duriez, Didier Junquero, Karine Valeille and Didier Cussac. Transcriptional and functional deregulations of lipid and cholesterol metabolism by antipsychotic compounds on rat primary hepatocytes. 3rd congres on prediabetes and the metabolic syndrome Nice, France, 2009.

  97. Peter Heusler, Amélie Tourette, Stéphanie Tardif, Didier Cussac. Partial agonist activity of (+)-OH-DPAT at human 2B adrenergic receptors. 3e Colloque Méditerranéen de Neurosciences, Alexandria, Egypte, 2009.

  98. Peter Heusler, Amélie Tourette, Claudie Cathala, Didier Cussac. N-methyl-D-aspartate channel blocking properties of dual reuptake inhibitors. World Pharma Copenhagen, Hollande, 2010.

  99. L. De Vries, C. Robichon, C. Cathala, M. Perez, D. Junquero and D. Cussac. Inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) secretion by prodomain overexpression or pefabloc treatment as measured by a luciferase assay. Experimental Biology Meeting, Anaheim, CA, USA, 2010.

  100. Jean-Claude Martel, Marie-Bernadette Assié, Peter Heusler, Didier Cussac, Pradeep Banerjee, Pierre Sokoloff In Vitro Characterization of F2695 (Levomilnacipran): A Serotonin-Norepinephrine Reuptake Inhibitor. Society for Neuroscience. San Diego, 2010.

  101. Jaroslava Buritova, Emilie Lauressergues, Fabrice Lestienne, Charlotte Theral, Catherine Barret-Grevoz, Géraldine Berrichon, Didier Cussac. Differential region-specific modulation of c-fos expression in rat brain induced by several 5-HT1A receptor agonists. 13th Word Congress on Pain, Montréal, 2010.

  102. De-Vries, L., Finana, F., Rauly-Lestienne, I., Lestienne, F., Ailhaud, M.C. & Cussac, D. Characterization of kinase inhibitors using a kinase binding assay on active/inactive TrkA/TrkB and a TrkB assay in neurons. Experimental Biology. 2011. Washington, DC.

  103. Luc De Vries, Frederic Finana and Didier Cussac. Development of an internalisation assay for G Protein Coupled Receptors and Receptor Tyrosine Kinases using Bioluminescence Resonance Energy Transfer (BRET) technology. FEBS Meeting, Séville, Spain 2012.

  104. L. De Vries, F. Finana, C. Cathala and D. Cussac. Novel internalisation assays for G protein Coupled Receptors using Bioluminescent Resonance Energy Transfer (BRET) technology. American Society for Cell Biology Annual Meeting, New Orleans, 2013.

  105. F. Finana, L. De Vries, C. Cathala and D. Cussac. A innovative assay based on Bioluminescent Resonance Energy Transfer (BRET) for real-time monitoring of cell surface-receptor internalization and trafficking.: Proof of concept with the dopamine D2S G protein Coupled Receptors. 10th European Functional Drug Screening Symposium. FDSS User Meeting, Allschwil, Switzerland, 2014.

  106. L. De Vries, F. Finana, C. Cathala and D. Cussac. Live cell internalisation assays using BRET technology with Rab markers to trace the destination of a G protein Coupled Receptors: the dopamine D2 receptor as an example. Gordon Conference on Lysosomes and Endocytosis, Andover, US, 2014.